HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

BACKGROUND: Neoadjuvant chemotherapy has been considered the standard care in locally advanced breast cancer. However, about 20% of the patients do not benefit from this clinical treatment and, predictive factors of response were not defined yet. This study was designed to evaluate the importance of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiezzi, Daniel G, Andrade, Jurandyr M, Ribeiro-Silva, Alfredo, Zola, Fábio E, Marana, Heitor RC, Tiezzi, Marcelo G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820790/
https://www.ncbi.nlm.nih.gov/pubmed/17324279
http://dx.doi.org/10.1186/1471-2407-7-36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820790/
https://www.ncbi.nlm.nih.gov/pubmed/17324279
http://dx.doi.org/10.1186/1471-2407-7-36

Ejemplares similares